HUMA Humacyte, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1818382 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY52.5%
TTM net income YoY-156.3%
TTM EPS YoY-66.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin-475.1%
Operating margin-4,602.9%
Net margin-3,955.1%
FCF margin-3,697.0%
EBITDA margin-4,381.8%
Returns
ROE-1,423.6%
ROA-87.3%
ROIC (approx.)—
Asset turnover0.02x
Leverage & solvency
Liabilities / assets85.6%
Debt / equity2.04x
Current ratio3.34x
Interest coverage-10.97x
Cash quality & payout
Operating cash flow / net income0.93x
Accruals ratio-6.0%
Payout ratio—
Capex / revenue13.3%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $2.04M | $0 |
| Cost of revenue | $9.70M | $0 |
| Gross profit | -$7.66M | $0 |
| R&D expense | $69.30M | $88.60M |
| SG&A expense | $31.17M | $25.80M |
| Operating income | -$108.14M | -$114.40M |
| Interest expense | $11.25M | $9.28M |
| Pretax income | -$40.83M | — |
| Income tax | $0 | $0 |
| Net income | -$40.83M | -$148.70M |
| EBITDA | -$102.81M | -$109.29M |
| EPS (basic) | -0.26 | -1.26 |
| EPS (diluted) | -0.26 | -1.26 |
| Weighted avg. shares (diluted) | 158.16M | 118.48M |
| Balance sheet | ||
| Cash & equivalents | $50.50M | $95.29M |
| Receivables | $441,000 | $0 |
| Inventory | $13.59M | $0 |
| Current assets | $67.80M | $47.86M |
| PP&E, net | $18.54M | $23.06M |
| Total assets | $116.37M | $137.87M |
| Current liabilities | $18.37M | $19.95M |
| Long-term debt | $35.44M | $0 |
| Total debt | $35.44M | $0 |
| Total liabilities | $113.26M | $190.54M |
| Shareholders' equity | $3.11M | -$52.67M |
| Net debt | -$15.05M | -$95.29M |
| Shares outstanding | 193.00M | 130.03M |
| Cash flow statement | ||
| Operating cash flow | -$105.04M | -$98.12M |
| Capital expenditure | $884,000 | $1.57M |
| Free cash flow | -$105.93M | -$99.69M |
| Investing cash flow | -$884,000 | -$1.57M |
| Financing cash flow | $61.49M | $114.18M |
| Depreciation & amortization | $5.33M | $5.10M |
| Stock-based compensation | $9.75M | $6.14M |
Free plan shows the latest 2 periods; Pro shows all 6 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.